Merck & Company Inc Market Cap ($316.95 Billion)
Market Cap & Net Worth: Merck & Company Inc (MRK)
Merck & Company Inc market cap. Merck & Company Inc (NYSE:MRK) has a market capitalization of $316.95 Billion ($316.95 Billion) as of November 4, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #54 globally and #38 in its home market, demonstrating a 2.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merck & Company Inc's stock price $148.36 by its total outstanding shares 2469824415 (2.47 Billion). Also see Merck & Company Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Merck & Company Inc Market Cap History (2015–2026)
Merck & Company Inc market cap history from 2015 to 2026. Data shows growth from $95.59 Billion to $366.42 Billion (13.30% CAGR). Check MRK share price today for real-time trading data and today's change.
Index Memberships
Merck & Company Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Composite Average
DJA
|
$17.86 Trillion | 1.77% | #15 of 65 |
|
DJC: Dow Jones-UBS Commodity Index
DJC
|
$24.80 Trillion | 0.79% | #14 of 65 |
|
Dow Jones Industrial Average
DJI
|
$23.06 Trillion | 1.20% | #14 of 30 |
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 9.19% | #4 of 24 |
|
S&P 500 Index
GSPC
|
$61.43 Trillion | 0.44% | #32 of 503 |
|
S&P 100
OEX
|
$44.08 Trillion | 0.63% | #31 of 101 |
Weight: Merck & Company Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Merck & Company Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Merck & Company Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Merck & Company Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.00x
Merck & Company Inc's market cap is 4.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.24x
Merck & Company Inc's market cap is 14.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $109.98 Billion | $39.81 Billion | $3.92 Billion | 2.76x | 28.06x |
| 2017 | $108.34 Billion | $40.12 Billion | $2.39 Billion | 2.70x | 45.26x |
| 2018 | $151.63 Billion | $42.29 Billion | $6.22 Billion | 3.59x | 24.38x |
| 2019 | $185.39 Billion | $39.12 Billion | $9.84 Billion | 4.74x | 18.84x |
| 2020 | $172.03 Billion | $41.52 Billion | $7.07 Billion | 4.14x | 24.34x |
| 2021 | $175.05 Billion | $48.70 Billion | $13.05 Billion | 3.59x | 13.41x |
| 2022 | $261.56 Billion | $59.28 Billion | $14.52 Billion | 4.41x | 18.02x |
| 2023 | $264.20 Billion | $60.12 Billion | $365.00 Million | 4.39x | 723.85x |
| 2024 | $245.70 Billion | $64.17 Billion | $17.12 Billion | 3.83x | 14.35x |
| 2025 | $259.97 Billion | $64.93 Billion | $18.25 Billion | 4.00x | 14.24x |
Competitor Companies of MRK by Market Capitalization
Companies near Merck & Company Inc in the global market cap rankings as of November 4, 2026. Also see MRK asset base for a full breakdown of the balance sheet.
Key companies related to Merck & Company Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- AstraZeneca PLC (MX:AZNN): Ranked #60 globally with a market cap of $290.50 Billion USD ( MX$5.05 Trillion MXN).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #60 | AstraZeneca PLC | MX:AZNN | $290.50 Billion | MX$1628.00 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.56 |
Market Capitalization of Merck & Company Inc (2015–2026)
Market capitalization of Merck & Company Inc from 2015 to today. Between 2015 and today, Merck & Company Inc's market cap moved from $95.59 Billion to $ 366.42 Billion, with a yearly change of 13.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $366.42 Billion | +40.95% |
| 2025 | $259.97 Billion | +5.81% |
| 2024 | $245.70 Billion | -7.00% |
| 2023 | $264.20 Billion | +1.01% |
| 2022 | $261.56 Billion | +49.42% |
| 2021 | $175.05 Billion | +1.75% |
| 2020 | $172.03 Billion | -7.21% |
| 2019 | $185.39 Billion | +22.27% |
| 2018 | $151.63 Billion | +39.95% |
| 2017 | $108.34 Billion | -1.49% |
| 2016 | $109.98 Billion | +15.05% |
| 2015 | $95.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Merck & Company Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $316.95 Billion USD |
| MoneyControl | $316.95 Billion USD |
| MarketWatch | $316.95 Billion USD |
| marketcap.company | $316.95 Billion USD |
| Reuters | $316.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more